Department of Internal Medicine, Kobe University Graduate School of Medicine, Chuo-ku, Kobe, Japan.
Pancreas. 2009 Nov;38(8):e207-14. doi: 10.1097/MPA.0b013e3181bb5037.
The rate of intraductal papillary mucinous neoplasm (IPMN) progression is much slower than that of invasive ductal adenocarcinomas. The identification of a clinicopathological marker to distinguish IPMNs from ductal adenocarcinomas is important for understanding the molecular mechanisms of pancreatic cancer.
We examined the expression pattern of the cell surface marker CD133, which has been used to identify putative cancer stem cells from solid tumors, in adult pancreatic ductal adenocarcinomas (n = 10) and IPMNs (n = 34).
CD133 expression was detected in the centroacinar region and intralobular ductal cells of normal pancreas. CD133 expression was also observed in ductal adenocarcinomas. In contrast, CD133 expression was not observed in the mucin-producing epithelial cells and carcinoma cells on IPMNs.
These results demonstrate that the expression of CD133 is down-regulated in IPMNs, suggesting that loss of CD133 expression might be a useful clinicopathological marker distinguishing IPMNs from ductal adenocarcinomas.
导管内乳头状黏液性肿瘤 (IPMN) 的进展速度远慢于浸润性导管腺癌。鉴定一种能够将 IPMN 与导管腺癌区分开的临床病理标志物对于理解胰腺癌的分子机制非常重要。
我们检测了细胞表面标志物 CD133 的表达模式，该标志物已被用于从实体瘤中鉴定出可能的癌症干细胞。我们检测了成人胰腺导管腺癌 (n = 10) 和 IPMN (n = 34) 中 CD133 的表达情况。
CD133 在正常胰腺的中心腺泡区和小叶内导管细胞中表达。CD133 在导管腺癌中也有表达。相比之下，CD133 在 IPMN 的黏液产生上皮细胞和癌细胞中不表达。
这些结果表明，CD133 在 IPMN 中表达下调，提示 CD133 表达缺失可能是一种有用的临床病理标志物，可将 IPMN 与导管腺癌区分开。
